Is apoCIII-Lowering A Double-Edged Sword?-Reference-Cited by-同舟云学术

Is apoCIII-Lowering A Double-Edged Sword?

Published:2022-07-01 Issue:7 Volume:29 Page:1117-1124
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Tang Xiangming¹,Zhou Huanjin²,Yan Haizhao³,Niimi Manabu¹,Fan Jianglin¹

Affiliation:

1. Department of Molecular Pathology, Faculty of Medicine, Interdisciplinary Graduate School of Medicine, University of Yamanashi

2. School of Biotechnology and Health Sciences, Wuyi University

3. Key Laboratory of Regenerative Biology, South China Institute for Stem Cell, Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/29/7/29_LE002/_pdf

Reference19 articles.

1. 1) Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem. Biophys. Res. Commun., 1972; 46: 375-382

2. 2) Brown WV, Levy RI, Fredrickson DS. Studies of the proteins in human plasma very low density lipoproteins. J. Biol. Chem., 1969; 244: 5687-5694

3. 3) Brewer HB, Jr., Shulman R, Herbert P, Ronan R, Wehrly K. The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. J. Biol. Chem., 1974; 249: 4975-4984

4. 4) Ramms B, Gordts P. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr. Opin. Lipidol., 2018; 29: 171-179

5. 5) Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: From pathophysiology to pharmacology. Trends Pharmacol. Sci., 2015; 36: 675-687